The prescribing information for Nubeqa (darolutamide) — used to treat men with prostate cancer that has not spread to other parts of the body — will be updated to ... Read more
A couple of weeks after its approval, Orgovyx (relugolix) is now commercially available in the U.S. for adults with advanced prostate cancer through authorized specialty distributors, the therapy’s developer, ... Read more
ARV-110, an investigational oral therapy that degrades the androgen receptor, has a favorable safety profile and showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer ... Read more
Long-term exposure to androgen deprivation therapy (ADT), a common treatment for prostate cancer, is associated with worse cardiorespiratory fitness and a higher risk of cardiovascular death, a new study ... Read more
The U.S. Food and Drug Administration (FDA) has approved Orgovyx (relugolix), an oral form of hormone therapy by Myovant Sciences, to treat adults with advanced prostate cancer. The approval, ... Read more
The philanthropic organization Prostate Cancer Foundation (PCF) and the charity Movember Foundation have announced the winners of the 2020 PCF Challenge Awards, an initiative that supports promising research in ... Read more
Researchers have developed a new technology that can be used to deliver the gene-editing tool CRISPR/Cas9 into prostate cancer cells without the need for viral vectors, a proof-of-concept study ... Read more
Canadian authorities have approved Lynparza (olaparib) as an oral treatment for people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA or ATM genes, both of which are involved ... Read more
The U.S. Food and Drug Administration (FDA) has granted fast track status to RV001, RhoVac‘s investigational therapy for prostate cancer, the company announced. Fast track designation helps speed the ... Read more
The U.S. Food and Drug Administration (FDA) has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as a positron emission tomography or PET imaging agent for men with prostate cancer. ... Read more
